Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/IIa, Open Label, Dose-escalating Clinical Study to Evaluate the Safety, Tolerability and Theraputic Effects of Transplantation of Astrocytes Derived From Human Embryonic Stem Cells (hESC), in Patients With Amyotrophic Lateral Sclerosis (ALS)

Trial Profile

A Phase I/IIa, Open Label, Dose-escalating Clinical Study to Evaluate the Safety, Tolerability and Theraputic Effects of Transplantation of Astrocytes Derived From Human Embryonic Stem Cells (hESC), in Patients With Amyotrophic Lateral Sclerosis (ALS)

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 24 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Stem cell therapies (Primary)
  • Indications Amyotrophic lateral sclerosis
  • Focus Adverse reactions
  • Sponsors Kadimastem
  • Most Recent Events

    • 24 Sep 2019 According to a Kadimastem media release, preliminary and interim results of Cohort A will be presented at the prestigious annual NEALS meeting at the beginning of October 2019. Final results of cohort A (total 6 months post treatment period) are expected by year-end 2019. Results of cohort B are expected in Q3, 2020. The trial is now continuing with higher doses and repeated injections.
    • 24 Sep 2019 Interim results of cohort A published in the Kadimastem Media Release
    • 18 Apr 2019 According to a Kadimastem media release, results for patients in cohort A are expected to be reported around the next four months or so.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top